Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Assets (2023 - 2026)

Prelude Therapeutics' Assets history spans 4 years, with the latest figure at $119.6 million for Q1 2026.

  • On a quarterly basis, Assets fell 15.3% to $119.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $119.6 million, a 15.3% decrease, with the full-year FY2025 number at $141.3 million, down 19.49% from a year prior.
  • Assets hit $119.6 million in Q1 2026 for Prelude Therapeutics, down from $141.3 million in the prior quarter.
  • Over the last five years, Assets for PRLD hit a ceiling of $277.7 million in Q4 2023 and a floor of $94.8 million in Q3 2025.
  • Historically, Assets has averaged $173.4 million across 4 years, with a median of $158.4 million in 2024.
  • Biggest five-year swings in Assets: tumbled 51.95% in 2025 and later decreased 15.3% in 2026.
  • Tracing PRLD's Assets over 4 years: stood at $277.7 million in 2023, then crashed by 36.79% to $175.5 million in 2024, then decreased by 19.49% to $141.3 million in 2025, then fell by 15.34% to $119.6 million in 2026.
  • Business Quant data shows Assets for PRLD at $119.6 million in Q1 2026, $141.3 million in Q4 2025, and $94.8 million in Q3 2025.